Slaughter and May advised Oxford Nanopore plc (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing technology, in connection with the subscription for newly issued ordinary shares (the “Subscription”) representing approximately 3.5% of Oxford Nanopore’s entire issued share capital prior to the investment by bioMérieux SA, a world leader in the field of in vitro diagnostics (“IVD”).
The primary investment, at a price of 238.08p per share, represents a total investment of nearly £70 million and a secondary investment up to an additional 3.5% of Oxford Nanopore’s shares is also anticipated, subject to availability and price.
As part of the Subscription, the two companies also agreed to establish an IVD Advisory Board to advance nanopore technology into routine clinical use.
Slaughter and May worked closely with the in-house legal team at Oxford Nanopore, including Jordan Herman (SVP, General Counsel) and Hannah Coote (Company Secretary).
David Meiklejohn / Trainee